93.79
1.41 (1.53%)
| Previous Close | 92.38 |
| Open | 91.22 |
| Volume | 273,922 |
| Avg. Volume (3M) | 512,717 |
| Market Cap | 3,540,587,520 |
| Price / Book | 6.14 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 4.64% |
| Current Ratio (MRQ) | 37.65 |
| Operating Cash Flow (TTM) | -101.70 M |
| Levered Free Cash Flow (TTM) | -66.74 M |
| Return on Assets (TTM) | -16.25% |
| Return on Equity (TTM) | -23.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Disc Medicine, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.65% |
| % Held by Institutions | 99.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 30 Sep 2025 | 2,142,617 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 153.00 (Cantor Fitzgerald, 63.13%) | Buy |
| Median | 114.50 (22.08%) | |
| Low | 108.00 (Raymond James, 15.15%) | Buy |
| Average | 120.83 (28.83%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 87.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 10 Nov 2025 | 114.00 (21.55%) | Buy | 83.58 |
| Stifel | 03 Nov 2025 | 125.00 (33.28%) | Buy | 84.69 |
| Morgan Stanley | 30 Oct 2025 | 115.00 (22.61%) | Buy | 85.75 |
| Cantor Fitzgerald | 17 Oct 2025 | 153.00 (63.13%) | Buy | 89.94 |
| Raymond James | 17 Oct 2025 | 108.00 (15.15%) | Buy | 89.94 |
| Wedbush | 17 Oct 2025 | 110.00 (17.28%) | Buy | 89.94 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |